Elevation Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 29
- Market Cap
- $45.7M
- Introduction
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Elevation Oncology
- Target Recruit Count
- 120
- Registration Number
- NCT05980416
- Locations
- 🇰🇷
Samsung Medical Center, Gangnam-Gu, Korea, Republic of
🇰🇷Yonsei University, Seodaemun-gu, Korea, Republic of
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Elevation Oncology
- Target Recruit Count
- 75
- Registration Number
- NCT04383210
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Elevation Oncology
- Target Recruit Count
- 22
- Registration Number
- NCT03241810
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸University of Mississippi, Jackson, Mississippi, United States
🇺🇸University of Utah Health Care - Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
- Conditions
- Interventions
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Elevation Oncology
- Target Recruit Count
- 153
- Registration Number
- NCT02387216
- Locations
- 🇫🇷
CHI Creteil, Créteil, Paris, France
🇫🇷Centre Léon Bérard, Lyon cedex 08, Rhône-Alpes, France